Hobart Laboratories

Executive Summary

Hobart Laboratories, founded in 1905, is a family-owned U.S. pharmaceutical company specializing in topical analgesics and poultices, with its flagship brand Numotizine® providing muscle and joint relief for both humans and animals, particularly horses. The company manufactures its products in an FDA-regulated facility and has built a trusted reputation over 60 years. As a private entity, Hobart operates in the stable but niche generic drugs market, with no disclosed pipeline or recent fundraising activities. Its growth potential lies in leveraging brand loyalty and regulatory compliance to expand product offerings or enter new animal health segments. However, limited innovation and lack of recent catalysts suggest modest near-term prospects.

Upcoming Catalysts (preview)

• Q3 2026Expansion of Numotizine into new veterinary markets40% success
• Q4 2026FDA approval of a new Numotizine formulation for human use (e.g., gel)30% success